Another excellent and perceptive piece. Dr. Love does a great job highlighting the extraordinary momentum in cancer treatment brought about by genetic engineering. The ability to reprogram the immune system, from ex vivo CAR T therapies to emerging in vivo approaches and CRISPR-edited TILs, represents a true leap forward in how we think about curing certain cancers rather than merely managing them.
What is especially encouraging is the way these technologies are beginning to converge: precise gene editing, enhanced targeting, and immune system reconditioning. The shift from custom-built cellular therapies to off-the-shelf or in vivo strategies could expand access dramatically while reducing cost and complexity.
We are witnessing a transition from proof of concept to scalable therapeutic innovation, and that is deeply hopeful. Of course, challenges remain, but the direction is unmistakably promising.
Thank you, John! I’m privileged to have authored a few studies in this very space, focused on CAR T for solid tumors, latent viral infections (HIV), and hematologic cancers.
The potential of GE technology is poorly understood by so many, and fear based on misinformation creates a snowball effect across all facets of human health—including our ability to grow food for 8+ billion people.
Great stuff Dr. Love. I was a fan and supporter before this, but as a CAR T patient, now 2 years free of lymphoma, I appreciate the extra background info and comparative argument with ag science.
Superbly done! As advanced as these therapies seem, we are just at the beginning of revolutionary approaches in cancer therapies. Ongoing efforts include getting the CAR T cells to work on solid tumors, being able to turn them on an off, and there is at least one company working on creating CAR T cells using mRNA in lipid vesicles (as the vaccines work), thereby reducing the time and effort to create CAR T cells. CAR T cells are also being tested to treat autoimmune diseases.
How can we counter the argument that GMOs might have adverse unintended consequences? Same would be a question for these medical therapies. Might they not have adverse unintended consequences as well?
Another excellent and perceptive piece. Dr. Love does a great job highlighting the extraordinary momentum in cancer treatment brought about by genetic engineering. The ability to reprogram the immune system, from ex vivo CAR T therapies to emerging in vivo approaches and CRISPR-edited TILs, represents a true leap forward in how we think about curing certain cancers rather than merely managing them.
What is especially encouraging is the way these technologies are beginning to converge: precise gene editing, enhanced targeting, and immune system reconditioning. The shift from custom-built cellular therapies to off-the-shelf or in vivo strategies could expand access dramatically while reducing cost and complexity.
We are witnessing a transition from proof of concept to scalable therapeutic innovation, and that is deeply hopeful. Of course, challenges remain, but the direction is unmistakably promising.
Thank you, John! I’m privileged to have authored a few studies in this very space, focused on CAR T for solid tumors, latent viral infections (HIV), and hematologic cancers.
The potential of GE technology is poorly understood by so many, and fear based on misinformation creates a snowball effect across all facets of human health—including our ability to grow food for 8+ billion people.
Yes, I appreciate your work and clarity. I am a fan!
Great stuff Dr. Love. I was a fan and supporter before this, but as a CAR T patient, now 2 years free of lymphoma, I appreciate the extra background info and comparative argument with ag science.
Superbly done! As advanced as these therapies seem, we are just at the beginning of revolutionary approaches in cancer therapies. Ongoing efforts include getting the CAR T cells to work on solid tumors, being able to turn them on an off, and there is at least one company working on creating CAR T cells using mRNA in lipid vesicles (as the vaccines work), thereby reducing the time and effort to create CAR T cells. CAR T cells are also being tested to treat autoimmune diseases.
How can we counter the argument that GMOs might have adverse unintended consequences? Same would be a question for these medical therapies. Might they not have adverse unintended consequences as well?